Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New Molecule Not Only Halts Heart Failure, But Also Improves Blood Pumping Capacity

By Kenny Walter | March 15, 2019

An international collaboration between researchers in the U.S. and Brazil has created a new molecule that stops the progression of heart failure while improving its capacity to pump blood.

The molecule, dubbed SAMβA (selective antagonist of mitofusin 1-β2PKC association), is able to inhibit the interaction between protein kinase C beta 2 (β2PKC) in heart cells and mitofusin 1 (mfn1), which is a crucial element of mitochondria, preventing the mitochondria from producing energy and ultimately weakening the heart’s blood-pumping action.

“This interaction was one of our main findings in this study. Its critical role in the progression of heart failure was previously unknown,” Julio Cesar Batista Ferreira, a professor at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil and principal investigator for the study, said in a statement. 

The researchers previously found that when inhibited, β2PKC, which is overproduced in failing heart cells, improved cardiac function, but prevented the protein from acting in other beneficial ways.

However, SAMβA is able to inhibit only β2PKC’s interaction with Mfn1 in mitochondria, while allowing the protein to conduct its other actions.

The researchers conducted tests with recombinant proteins, cells, animals and samples of cardiac tissue from patients with heart failure to create the new molecule.

First, they conducted different in vitro experiments, testing the interaction between β2PKC and Mfn1. This resulted in six molecules that inhibited the interaction, with only SAMβA able to selectively inhibit without interfering with other interactions.

The researchers then moved on to testing their molecules in human hearts and found that the molecule boosted human heart cells’ capacity to contract. They also found that SAMβA reduced the amount of hydrogen peroxide in heart cell mitochondria, which is a trigger of cardiac cell degeneration.

In the final phase of the study, the researched induced myocardial infarction in rats. After one month, the rat developed heart failure, causing the researchers to implant an osmotic pump under their skin that releases small amounts of either SAMβA or an innocuous substance.

After six weeks of treatment, the rats that were treated with the molecule stopped showing heart failure and their cardiac function improved, while the control group rats did not.

“The drugs in current use halt progression of the disease but never make it regress,” Ferreira said. “We showed that by regulating this specific interaction, we could both halt progression and make the disease regress to a less severe stage.”

The researchers now plan to make the molecule available for other researchers to test against other diseases in different experimental models. They also plan to test the molecule’s interaction with other drugs currently used to treat heart failure.

Heart attacks generally occur when a blocked coronary artery prevents blood from reaching a section of the heart. The remainder of the cardiac tissue is then overloaded, reducing the heart’s capacity to pump blood throughout the body gradually over time. The researchers believe that the new molecule could augment or replace some of the outdated heart medications developed as far back as the 1980s.

According to the World Health Organization, cardiovascular disease kills 17.9 million people annually worldwide, accounting for 31 percent of all global deaths. 

SAMβA is currently in use in the U.S. and the researchers have already applied for a patent.   After the patent is granted, they can test the molecule in connection with hypertension and other cardiovascular diseases.

The study was published in Nature Communications.

 

 

      

 

 

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE